Skip to main content
. 2023 Jan 13;30(5):2916–2925. doi: 10.1245/s10434-022-13089-5

Fig. 2.

Fig. 2

Cumulative risk of disease recurrence according to primary tumor size in each WHO 2017 classification. A Overall patients; B patients with wild-type TERT; and C patients with mutant TERT. EA-FTC encapsulated angioinvasive FTC, FTC follicular thyroid carcinoma, MI-FTC minimally invasive FTC, TERT telomerase reverse transcriptase, WI-FTC widely invasive FTC